title: Clinicopathologic characteristics and survival of male breast cancer.
abstract: BACKGROUND
  Male breast cancer (MBC) is a rare disease and accounts for <1 % of all breast cancers.
  
  
  METHODS
  We retrospectively analyzed clinicopathologic characteristics and prognosis of MBC patients who were diagnosed in our hospital between March 2002 and March 2012.
  
  
  RESULTS
  The median age of diagnosis of MBC was 62 years, which was 9 years older than female breast cancer (FBC) patients. The highest proportion of MBC patients was in the 50-59-year age group. The percentage of invasive ductal carcinoma in MBC was much higher than in FBC (P = 0.000). The positive rate of estrogen receptors in MBC patients (87.9 %) was significantly higher than in FBC patients (P = 0.048), whereas HER-2 was positive in 17.2 % of MBC patients, which was significantly lower than in FBC patients (P = 0.001). There was a consistent significant difference in luminal subtypes of FBC and MBC patients (P = 0.000). The overall survival rates of MBC were significantly higher than FBC (P = 0.004). HER-2-positive patients had a statistically worse prognosis than HER-2-negative patients (P = 0.040). Lymph node metastasis and larger tumor size were also associated with poorer prognosis (P = 0.056 and P = 0.088). The level of hormones was examined in 7 patients, and abnormal hormone levels were detected in 4.
  
  
  CONCLUSIONS
  The FBC patients were significantly different from the MBC in clinicopathologic and prognostic characteristics. HER-2 positivity was an important factor for prognosis.
authors: Department of Integrated Traditional and Western Medicine, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
authors: Dongying
authors: D
authors: Liu
authors: Guangru
authors: G
authors: Xie
authors: Ming
authors: M
authors: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018567:Breast Neoplasms, Male / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
references: Ann Surg. 1992 May;215(5):451-7; discussion 457-9
references: 1319699
references: Eur J Cancer. 1998 Aug;34(9):1341-7
references: 9849414
references: Tumori. 1990 Feb 28;76(1):26-8
references: 2321270
references: Maturitas. 2010 Apr;65(4):308-14
references: 20138719
references: Breast J. 2012 Jan-Feb;18(1):65-8
references: 22017630
references: Br J Cancer. 1983 Sep;48(3):423-7
references: 6684472
references: J Steroid Biochem. 1976 Aug;7:605-9
references: 134178
references: J Epidemiol. 2001 Jan;11(1):1-7
references: 11253905
references: Lancet. 1995 Aug 26;346(8974):544-5
references: 7658781
references: Cancer. 2004 Jul 1;101(1):51-7
references: 15221988
references: Ann Epidemiol. 2005 Nov;15(10):773-80
references: 16257362
references: Breast J. 2011 Sep-Oct;17(5):503-9
references: 21883641
references: BMC Res Notes. 2011 Jun 29;4:219
references: 21714875
references: Breast Cancer Res Treat. 2004 Apr;84(3):215-23
references: 15026619
references: Pathobiology. 2007;74(6):323-7
references: 18087196
references: Breast. 2012 Jun;21(3):237-41
references: 22300703
references: Breast. 2010 Dec;19(6):450-5
references: 20494580
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55
references: 19427229
references: Br J Cancer. 1999 Feb;79(5-6):959-64
references: 10070897
references: Cancer. 1996 Feb 1;77(3):490-8
references: 8630956
references: Breast Cancer Res Treat. 2007 Oct;105(2):169-75
references: 17268818
references: Clin Breast Cancer. 2011 Mar;11(1):39-45
references: 21421521
references: Eur J Cancer. 1994;30A(7):930-5
references: 7946586
references: Am J Gastroenterol. 1996 Feb;91(2):380-2
references: 8607512
references: Med Oncol. 2012 Jun;29(2):554-60
references: 21573973
references: Breast Cancer Res Treat. 2004 Jan;83(1):77-86
references: 14997057
references: IARC Sci Publ. 2008;(160):1-837
references: 19388204
references: Am J Epidemiol. 1992 Apr 1;135(7):734-48
references: 1350708
references: J Clin Oncol. 2010 Jan 10;28(2):232-9
references: 19996029
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153
references: Breast Care (Basel). 2011 Dec;6(6):446-451
references: 22419898
references: Int J Cancer. 1992 Apr 22;51(1):62-6
references: 1563846
references: BMC Cancer. 2011 Aug 04;11:335
references: 21816051
references: Oncologist. 2005 Aug;10(7):471-9
references: 16079314
references: J Clin Oncol. 1984 Aug;2(8):903-9
references: 6086848